The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2015 | Towards new combination therapies for the treatment of chronic lymphocytic leukemia

Name: Towards new combination therapies for the treatment of chronic lymphocytic leukemia
Uploaded: 2015-06-12T00:00:00.000Z
Duration: 1 min 23 s
Description: At the 20th Congress of the European Hematology Association (EHA), Paolo Ghia, MD, PhD, of Università Vita-Salute San Raffaele, Milan, Italy, discusses the development of new and more effective therapies, which are focusing on anti-CD20 monoclonal antibody-containing regimens, for the treatment of patients with chronic lymphocytic leukemia.

Paolo Ghia • 12 Jun 2015

EHA 2015

Chronic Lymphocytic Leukemia

At the 20th Congress of the European Hematology Association (EHA), Paolo Ghia, MD, PhD, of Università Vita-Salute San Raffaele, Milan, Italy, discusses the development of new and more effective therapies, which are focusing on anti-CD20 monoclonal antibody-containing regimens, for the treatment of patients with chronic lymphocytic leukemia.